Autolus Therapeutics plc (AUTL)
Market Cap | 899.20M |
Revenue (ttm) | 10.50M |
Net Income (ttm) | -221.26M |
Shares Out | 266.04M |
EPS (ttm) | -1.21 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,545,742 |
Open | 3.440 |
Previous Close | 3.470 |
Day's Range | 3.310 - 3.470 |
52-Week Range | 2.010 - 7.450 |
Beta | 2.02 |
Analysts | Strong Buy |
Price Target | 9.33 (+176.04%) |
Earnings Date | Aug 1, 2024 |
About AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell ly... [Read more]
Financial Performance
In 2023, AUTL's revenue was $1.70 million, a decrease of -73.30% compared to the previous year's $6.36 million. Losses were -$208.38 million, 40.0% more than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for AUTL stock is "Strong Buy." The 12-month stock price forecast is $9.33, which is an increase of 176.04% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/g/u/conf17-2479443.jpg)
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces th...
![](https://cdn.snapi.dev/images/v1/u/t/press15-2455943.jpg)
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent ste...
![](https://cdn.snapi.dev/images/v1/h/e/press11-2436745.jpg)
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHA Two patients enrolled in Phase 1 Systemic Lupus Erythematosus (SLE) trial...
![](https://cdn.snapi.dev/images/v1/b/b/press10-2388269.jpg)
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces t...
![](https://cdn.snapi.dev/images/v1/s/n/conf4-2384924.jpg)
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t...
![](https://cdn.snapi.dev/images/v1/d/z/press13-2349421.jpg)
Autolus Therapeutics Announces Changes to its Board of Directors
LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces t...
![](https://cdn.snapi.dev/images/v1/x/s/press10-2323912.jpg)
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
Announced strategic collaboration and equity investment from BioNTech for aggregate proceeds of $250 million upfront, plus underwritten offering of ADSs for $350 million, for gross proceeds of $600 mi...
![](https://cdn.snapi.dev/images/v1/m/p/press20-2319521.jpg)
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
LONDON, March 12, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces t...
![](https://cdn.snapi.dev/images/v1/f/l/conf10-2300671.jpg)
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces th...
![](https://cdn.snapi.dev/images/v1/g/c/press1-2266543.jpg)
Autolus Announces Pricing of Underwritten Offering
LONDON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...
![](https://cdn.snapi.dev/images/v1/u/r/press11-2266370.jpg)
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies' autologous CAR-T programs towards market, pending market authoriz...
![](https://cdn.snapi.dev/images/v1/q/j/press16-2239829.jpg)
Autolus Therapeutics announces publication in ACS Chemical Biology
LONDON, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a ...
![](https://cdn.snapi.dev/images/v1/u/l/press20-2237900.jpg)
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
PDUFA Goal date is November 16, 2024 Company on track to submit a marketing authorization application to the European Medicines Agency (EMA) in the first half of 2024 LONDON, Jan. 22, 2024 (GLOBE NEWS...
![](https://cdn.snapi.dev/images/v1/c/a/press1-2190245.jpg)
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Pooled analysis of the FELIX Phase Ib/II study demonstrated prolonged event free survival and low overall immunotoxicity across all cohorts in r/r B-ALL, and particularly in patients with low leukemic...
![](https://cdn.snapi.dev/images/v1/w/l/press12-2171855.jpg)
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
BLA submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) Company on track to submit a marketing ...
![](https://cdn.snapi.dev/images/v1/y/c/press19-2158856.jpg)
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
In-person and webcast event on Sunday, 10 December, 2023 at 8:00 AM PT / 4:00 PM GMT Review of pooled analysis of the ongoing FELIX Phase Ib/II study, pooled analysis from ALLCAR19 and FELIX Phase Ib ...
![](https://cdn.snapi.dev/images/v1/5/x/conf3-2141109.jpg)
Autolus Therapeutics announces participation in upcoming conferences
LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces it...
![](https://cdn.snapi.dev/images/v1/f/z/press3-2135601.jpg)
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US...
![](https://cdn.snapi.dev/images/v1/a/o/press12-2106113.jpg)
Autolus Therapeutics to host virtual event to discuss the company's obe-cel program in systemic lupus erythematosus
LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...
![](https://cdn.snapi.dev/images/v1/y/t/conf3-2098529.jpg)
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...
![](https://cdn.snapi.dev/images/v1/e/q/conf2-2098304.jpg)
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...
![](https://cdn.snapi.dev/images/v1/j/v/press12-2003911.jpg)
Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced it...
![](https://cdn.snapi.dev/images/v1/t/7/press7-1977503.jpg)
Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer
- Veronica Hersberger appointed as Senior Vice President, Medical Affairs- Miranda Neville promoted to Senior Vice President, Project Management and will continue to lead the obe-cel program
![](https://cdn.snapi.dev/images/v1/x/v/conf12-1975375.jpg)
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...
![](https://cdn.snapi.dev/images/v1/f/c/press15-1949100.jpg)
Autolus Therapeutics announces publication in Cancer Immunology Research
LONDON, June 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a ...